Meeting
2023 ASCO Breakthrough
Disparities in African-American patient enrollment in pivotal phase 3 immunotherapy trials that led to FDA drug approval in patients with non-small cell lung cancer.
Authors
Chimezie Ubbaonu
University of California Irvine, Orange
Chimezie Ubbaonu , Sai-Hong Ignatius Ou
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Gastrointestinal Cancer,Gynecologic Cancer,Head and Neck Cancer,Quality of Care,Genetics/Genomics/Multiomics,Healthcare Equity and Access to Care,Healthtech Innovations,Models of Care and Care Delivery,Population Health,Viral-Mediated Malignancies
Sub Track
Immunotherapies
Citation
JCO Global Oncology 9, 2023 (suppl 1; abstr 99)
DOI
10.1200/GO.2023.9.Supplement_1.99
Abstract #
99
Poster Bd #
F4
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Quality Care Symposium
Post-protocol therapies in first-line immunotherapy trials in non–small cell lung cancer (NSCLC).
First Author: Aakash Desai
Poster
2022 ASCO Annual Meeting
Differential prognostic effect of systemic inflammation in patients with NSCLC treated with immunotherapy or chemotherapy: A post hoc analysis of the phase III OAK trial.
First Author: Alessio Cortellini
Poster
2022 ASCO Annual Meeting
Clinical outcome and potential benefits of post-progression immunotherapy for patients with metastatic NSCLC with primary resistance to ipilumumab and nivolumab in the LONESTAR phase III study.
First Author: Mehmet Altan
Poster
2022 ASCO Annual Meeting
Incidence and impact of proportional hazards violations in phase 3 cancer clinical trials.
First Author: Timothy Lin